10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Gentamicin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Gentamicin

Gentamicin

Class : A

Show all info

Print

Contact us

  1. Rocha JL, Tuon FF, Johnson JR. Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Braz J Infect Dis. 2012;16:115-21.

  2. Gonçalves-Pereira J, Martins A, Póvoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect. 2010;16:1258-63.

  3. Gensumycin (gentamicin). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.

  4. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.

  5. Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol. 1995;26:1477-87.

  6. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100:352-7.

  7. Prince RA, Ling MH, Hepler CD, Rainville EC, Kealey GP, Donta ST et al. Factors associated with creatinine clearance changes following gentamicin therapy. Am J Hosp Pharm. 1980;37:1489-95.

  8. Sweileh WM. Gender differences in aminoglycoside induced nephrotoxicity: a prospective, hospital-based study. Curr Clin Pharmacol. 2009;4:229-32.

  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-06-30.]

  1. Rocha JL, Tuon FF, Johnson JR. Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Braz J Infect Dis. 2012;16:115-21.
  2. Gonçalves-Pereira J, Martins A, Póvoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect. 2010;16:1258-63.
  3. Gensumycin (gentamicin). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.
  4. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.
  5. Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol. 1995;26:1477-87.
  6. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100:352-7.
  7. Prince RA, Ling MH, Hepler CD, Rainville EC, Kealey GP, Donta ST et al. Factors associated with creatinine clearance changes following gentamicin therapy. Am J Hosp Pharm. 1980;37:1489-95.
  8. Sweileh WM. Gender differences in aminoglycoside induced nephrotoxicity: a prospective, hospital-based study. Curr Clin Pharmacol. 2009;4:229-32.
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-06-30.]